Indications
Seberb 250 Tablet is used for:
Non-small Cell Lung Cancer
Adult Dose
Oral
Locally advanced or metastatic non-small cell lung carcinoma
Adult: 250 mg once daily until disease progression or unacceptable toxicity
Child Dose
Renal Dose
Administration
Film-coated tab: May be taken with or without food. May also be dispersed in ½ glass of plain, non-carbonated water. No other liqd should be used. Drop the tab in water & stir w/o crushing until it disperses (approx 10 min). Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via NG tube.
Contra Indications
Hypersensitivity. Lactation.
Precautions
Patients w/ concurrent idiopathic pulmonary fibrosis, acute onset or worsening pulmonary or eye symptoms. Renal and hepatic impairment. Pregnancy. Monitoring Parameters Monitor liver function, prothrombin time or INR frequently.
Lactation
Unknown if distributed in human breast milk; not recommended
Pregnancy-Lactation
Pregnancy
Based on its mechanism of action and animal data, gefitinib can cause fetal harm when administered to a pregnant woman
Advise females of reproductive potential to use effective contraception during treatment with gefitinib and for at least 2 weeks following completion of therapy
Advise pregnant women of the potential hazard to a fetus or potential risk for loss of the pregnancy
Lactation
Unknown if distributed in human breast milk; not recommended
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Interactions
Concomitant use w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, barbiturates) may reduce serum gefitinib levels. Plasma concentrations may be increased w/ potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole). Increased INR or bleeding events w/ warfarin. May increase plasma levels of metoprolol. May exacerbate vinorelbine-induced neutropenia. Decreased plasma levels and potential reduction in efficacy w/ drugs that affect gastric pH (e.g. PPIs, H2-receptor antagonists).
Side Effects
Side effects of Gefitinib :
>10%
Skin reactions, all grades (47%), Diarrhea, all grades (29%), Decreased appetite, all grades (17%), Vomiting, all grades (14%), Increased ALT, all grades (11.4%)
1-10%
Increased AST, all grades (7.9%), Stomatitis, all grades (7%), Conjunctivitis, blepharitis, and dry eye (6.7%), Conjunctivitis/blepharitis/dry eye (6%), Increased ALT, grades 3-4 (5.1%), Nail disorders, all grades (5%), Diarrhea, grades 3-4 (3%), Increased AST, grades 3-4 (3%), Increased bilirubin, all grades (2.7%), Decreased appetite, grades 2-3 (2.3%), Skin reactions, grades 3-4 (2%), Interstitial lung disease, all grades (1.3%), Vomiting, grades 3-4 (1.2%)
<1%
Interstitial lung disease, grades 3-4 (0.7%), Increased bilirubin, grades 3-4 (0.7%), Stomatitis, all grades (0.3%), Corneal erosion and aberrant eyelash growth (0.2%), Nail disorders, grades 3-4 (0.1%), Gastrointestinal perforation (0.1%), Ocular keratitis (0.1%), Erythema multiforme and dermatitis bullous (0.08%), Fatal hepatoxicity (0.04%)
Mode of Action
Gefitinib is a synthetic anilinoquinazoline which inhibits the intracellular phosphorylation of numerous tyrosine kinases associated w/ transmembrane cell surface receptors found on both normal and cancer cells, including epidermal growth factor receptor (EGFR) tyrosine kinase. Tyrosine kinase activity appears to be essentially important to cell proliferation and survival.
Note
Seberb 250 250mg Tablet generic name is Gefitinib. Seberb 250 250mg Tablet is manufactured by Genvio Pharma Ltd.Seberb 250 is availble in all over Bangladesh.
Mes BD drug index information on Seberb 250 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.